A Phase 3 interventional study of IgPro20 and Placebo in Post-COVID Postural Orthostatic Tachycardia Syndrome, sponsored by CSL Behring. Terminated at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States — 19 open to participants now, 42 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · United States.
Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, this one is the 55th largest by enrollment of the 67 interventional ones that give a count, is one of 8 that started in 2024, is one of 2 in phase 3, and was the 80th registered.
136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.
Browse Postural Orthostatic Tachycardia Syndrome studies →19 of the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Blueprint Medicines Corporation · Sites in United States, Belgium
Ages 18+
Stanford University · Sites in United States
Ages 18+
Virginia Commonwealth University · Sites in United States
Ages 12–21 · Women only · Healthy volunteers
University of Texas Southwestern Medical Center · Sites in United States
Ages 14+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 3 · Phase 4 1
First in 1994; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 36 across 102 interventional studies indexed under Postural Orthostatic Tachycardia Syndrome.
Median enrollment 36 across the 67 interventional studies, 100 across the 25 observational. Of the 49 that completed or were terminated, 19 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 92 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 1 study filed under Postural Orthostatic Tachycardia Syndrome — fewer than ten, so there is no comparison to draw.
11 of the studies in Postural Orthostatic Tachycardia Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00962728Alfredo GamboaBreathing Device in Postural Orthostatic Tachycardia Syndrome (POTS) | 2026-11 |
| NCT07197905Vanderbilt University Medical CenterRestoring Iron Deficiency in POTS | 2026-12 |
| NCT01988883Vanderbilt University Medical CenterModafinil and Cognitive Function in POTS | 2026-12 |
| NCT01783288Vanderbilt UniversityAldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening | 2026-12 |
| NCT05618054Virginia Commonwealth UniversityPeriaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities? | 2026-12 |
Add all 11 to your calendar (.ics) → With an account.
Among the 92 studies in Postural Orthostatic Tachycardia Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 [COVID-19] POTS [post-COVID-POTS]).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: IgPro20
Biological: Placebo
IgPro20 is a 20% ready-to-use liquid formulation of polyvalent human immunoglobulin G (IgG) for subcutaneous (SC) administration
Also known as: HIZENTRA®
2% human albumin solution administered subcutaneously as a volume-matched dose to the experimental IMP.
Proportion of Participants No Longer Meeting Diagnostic Criteria of Post-COVID POTS as Measured by Standardized Standing Test (ie, No Longer Experiencing HR Increase of ≥30 Bpm, in the Absence of 20 mmHg Decrease of SBP [Orthostatic Hypotension])
The reported data reflect the percentage of participants who no longer met the diagnostic criteria for Post-Coronavirus Disease 2019 (COVID) Postural Orthostatic Tachycardia Syndrome (POTS), as assessed by a standardized standing test (i.e., no longer experiencing a heart-rate (HR) increase of \>=30 bpm in the absence of a 20 mmHg decrease in systolic blood pressure \[SBP; orthostatic hypotension\]), among participants evaluated at that visit. The Baseline data represent the proportion of participants who were meeting the diagnostic criteria for post-COVID POTS.
Time frame: At Baseline and at Week 25
Change From Baseline in Orthostatic Intolerance (OI) Score of Composite Autonomic Symptom Score 31 (COMPASS-31)
The COMPASS-31 was a self-reported questionnaire that measures autonomic symptoms across six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. The OI domain assesses symptoms including faintness, dizziness, feeling "goofy," or had difficulty thinking soon after standing up from a sitting or lying position, and generates a total score ranging from 0 to 40 with higher scores representing a higher symptom burden. The treatment effect of interest was the difference from baseline in OI score of COMPASS-31. A more negative change from baseline indicates a greater improvement in OI symptoms.
Time frame: At Baseline and at Week 25
Change From Baseline in COMPASS-31 Total Score
The COMPASS-31 was a self-reported questionnaire that measured autonomic symptoms related to six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. This questionnaire generated a weighted score ranging from 0 to 100, with higher scores representing a higher symptom burden. A COMPASS-31 score of \>=40 indicated that participants had severe autonomic dysfunction. A more negative change from baseline indicates a greater improvement in autonomic symptoms.
Time frame: At Baseline and at Week 25
Change From Baseline in Heart Rate Increase Within 10 Minutes of Standing Test
Heart rate for the standing test was measured at the end of 10 minutes in the supine position and at 1, 3, 5, 7, and 10 minutes of standing. The change in heart rate during the standing test was calculated as the difference between the average of the two highest heart rate measurements (bpm) within 10 minutes of standing and the heart rate measurement (bpm) at the end of 10 minutes in the supine position.
Time frame: At Baseline and at Week 25
Number of Participants With Treatment-Emergent Adverse Event (TEAE), Related TEAE, Serious TEAE and Related Serious TEAE
Time frame: Up to Week 45
Percentage of Participants With TEAE, Related TEAE, Serious TEAE and Related Serious TEAE
The participant data were rounded to one decimal place.
Time frame: Up to Week 45
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Time frame: Up to Week 45
Percentage of Participants With Clinically Significant ECG Abnormalities
Time frame: Up to Week 45
Number of Participants With Change From Baseline in Clinically Significant ECG Abnormalities
Time frame: From Baseline up to Week 45
Percentage of Participants With Change From Baseline in Clinically Significant ECG Abnormalities
Time frame: From Baseline up to Week 45
This study was conducted in the United States.
| Milestone | IgPro20/IgPro20 | Placebo/IgPro20 |
|---|---|---|
| Started | 11 | 5 |
| Completed | 3 | 0 |
| Not completed | 8 | 5 |
| Withdrew: Study terminated by sponsor | 8 | 5 |
| Milestone | IgPro20/IgPro20 | Placebo/IgPro20 |
|---|---|---|
| Started | 3 | 0 |
| Completed | 0 | 0 |
| Not completed | 3 | 0 |
| Withdrew: Study terminated by sponsor | 3 | 0 |
The reported data reflect the percentage of participants who no longer met the diagnostic criteria for Post-Coronavirus Disease 2019 (COVID) Postural Orthostatic Tachycardia Syndrome (POTS), as assessed by a standardized standing test (i.e., no longer experiencing a heart-rate (HR) increase of \>=30 bpm in the absence of a 20 mmHg decrease in systolic blood pressure \[SBP; orthostatic hypotension\]), among participants evaluated at that visit. The Baseline data represent the proportion of participants who were meeting the diagnostic criteria for post-COVID POTS.
| Percentage of participants | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) |
|---|---|---|
| At Baseline | 100 | 100 |
| At Week 25 | 33.3 | — |
The COMPASS-31 was a self-reported questionnaire that measures autonomic symptoms across six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. The OI domain assesses symptoms including faintness, dizziness, feeling "goofy," or had difficulty thinking soon after standing up from a sitting or lying position, and generates a total score ranging from 0 to 40 with higher scores representing a higher symptom burden. The treatment effect of interest was the difference from baseline in OI score of COMPASS-31. A more negative change from baseline indicates a greater improvement in OI symptoms.
| Score on a scale | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) |
|---|---|---|
| Change From Baseline in Orthostatic Intolerance (OI) Score of Composite Autonomic Symptom Score 31 (COMPASS-31) | -25.3 ± 10.07 | — |
The COMPASS-31 was a self-reported questionnaire that measured autonomic symptoms related to six domains: OI, vasomotor, secretomotor, gastrointestinal (GI), bladder, and pupillomotor. This questionnaire generated a weighted score ranging from 0 to 100, with higher scores representing a higher symptom burden. A COMPASS-31 score of \>=40 indicated that participants had severe autonomic dysfunction. A more negative change from baseline indicates a greater improvement in autonomic symptoms.
| Score on a scale | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) |
|---|---|---|
| Change From Baseline in COMPASS-31 Total Score | -46.65 ± 6.014 | — |
Heart rate for the standing test was measured at the end of 10 minutes in the supine position and at 1, 3, 5, 7, and 10 minutes of standing. The change in heart rate during the standing test was calculated as the difference between the average of the two highest heart rate measurements (bpm) within 10 minutes of standing and the heart rate measurement (bpm) at the end of 10 minutes in the supine position.
| Beats per minute | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) |
|---|---|---|
| Change From Baseline in Heart Rate Increase Within 10 Minutes of Standing Test | -13.25 ± 6.718 | — |
| Participants | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) | IgPro20 (Open-label Period) |
|---|---|---|---|
| Any TEAE | 10 | 4 | 0 |
| Any TEAE Related to Study Treatment | 9 | 0 | 0 |
| Any Serious TEAE | 0 | 0 | 0 |
| Any Serious TEAE Related to Study Treatment | 0 | 0 | 0 |
The participant data were rounded to one decimal place.
| Percentage of participants | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) | IgPro20 (Open-label Period) |
|---|---|---|---|
| Any TEAE | 90.9 | 80.0 | 0 |
| Any TEAE Related to Study Treatment | 81.8 | 0 | 0 |
| Any Serious TEAE | 0 | 0 | 0 |
| Any Serious TEAE Related to Study Treatment | 0 | 0 | 0 |
| Participants | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) | IgPro20 (Open-label Period) |
|---|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 | 0 | 0 |
| Percentage of participants | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) | IgPro20 (Open-label Period) |
|---|---|---|---|
| Percentage of Participants With Clinically Significant ECG Abnormalities | 0 | 0 | 0 |
| Participants | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) | IgPro20 (Open-label Period) |
|---|---|---|---|
| Number of Participants With Change From Baseline in Clinically Significant ECG Abnormalities | 0 | 0 | 0 |
| Percentage of participants | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) | IgPro20 (Open-label Period) |
|---|---|---|---|
| Percentage of Participants With Change From Baseline in Clinically Significant ECG Abnormalities | 0 | 0 | 0 |
Collected over Up to Week 45. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IgPro20 (Double-blind Period) | 0/11 (0%) | 0/11 (0%) | 10/11 (90.9%) |
| Placebo (Double-blind Period) | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| IgPro20 (Open-label Period) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
| Event | IgPro20 (Double-blind Period) | Placebo (Double-blind Period) | IgPro20 (Open-label Period) |
|---|---|---|---|
| Infusion site painGeneral disorders | 3/11 | 1/5 | 0/3 |
| Injection site painGeneral disorders | 3/11 | 0/5 | 0/3 |
| FatigueGeneral disorders | 0/11 | 1/5 | 0/3 |
| Infusion site haemorrhageGeneral disorders | 0/11 | 1/5 | 0/3 |
| HeadacheNervous system disorders | 2/11 | 1/5 | 0/3 |
| Balance disorderNervous system disorders | 0/11 | 1/5 | 0/3 |
| DizzinessNervous system disorders | 0/11 | 1/5 | 0/3 |
| Neuropathy peripheralNervous system disorders | 0/11 | 1/5 | 0/3 |
| Grip strength decreasedInvestigations | 0/11 | 1/5 | 0/3 |
| BronchitisInfections and infestations | 0/11 | 1/5 | 0/3 |
The Intention-to-Treat (ITT) analysis set included all participants in the Screened Analysis Set (SAS) who were randomized into the study.
| Age, Categorical(Participants) | IgPro20/IgPro20 | Placebo/IgPro20 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 5 | 16 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(Years) | IgPro20/IgPro20 | Placebo/IgPro20 | Total |
|---|---|---|---|
| Mean | 31.2 ± 8.78 | 37.8 ± 8.47 | 33.3 ± 8.98 |
| Sex: Female, Male(Participants) | IgPro20/IgPro20 | Placebo/IgPro20 | Total |
|---|---|---|---|
| Female | 7 | 4 | 11 |
| Male | 4 | 1 | 5 |
| Ethnicity (NIH/OMB)(Participants) | IgPro20/IgPro20 | Placebo/IgPro20 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 9 | 5 | 14 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | IgPro20/IgPro20 | Placebo/IgPro20 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 11 | 3 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider on a case-by-case basis requests to share Individual Patient Data (IPD) with external bona-fide, qualified scientific and medical researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Requests for IPD will generally be considered once review by major regulatory authorities (ie FDA, EMA) is complete and the primary publication is available.
Access criteria: Proposed research should seek to answer a previously unanswered important medical or scientific question. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Ran from Aug 2024 to primary completion in Jun 2025, 9 months.
Results were first posted in Apr 2026, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hizentra
Postural Orthostatic Tachycardia Syndrome →